Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial

This publication has 39 references indexed in Scilit:

• Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle
  Journal of Clinical Oncology, 2005
• Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma
  New England Journal of Medicine, 2005
• A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer
  Clinical Cancer Research, 2005
• Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)
  Annals of Oncology, 2005
• Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015)
  Journal of Clinical Oncology, 2004
• Proteasome Inhibition Sensitizes Non–Small-Cell Lung Cancer to Gemcitabine-Induced Apoptosis
  The Annals of Thoracic Surgery, 2004
• A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
  British Journal of Haematology, 2004
• Thalidomide Alone or With Dexamethasone for Previously Untreated Multiple Myeloma
  Journal of Clinical Oncology, 2003
• The ubiquitin‐proteasome pathway and proteasome inhibitors
  Medicinal Research Reviews, 2001
• New Guidelines to Evaluate the Response to Treatment in Solid Tumors
  JNCI Journal of the National Cancer Institute, 2000